Tafasitamab Plus Lenalidomide and R-CHOP Cuts Progression Risk in High-Risk DLBCL

Adding tafasitamab (Monjuvi) and lenalidomide (Revlimid) to standard R-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, and prednisone) chemotherapy reduced the risk of disease progression or death by 25% compared with R-CHOP alone in patients with newly diagnosed, high-risk diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL), according to primary results from the phase 3 frontMIND trial (NCT04824092) presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.¹

At the data cutoff of October 20, 2025, the findings met the trial's primary end point of investigator-assessed progression-free survival (PFS), with an HR of 0.75 (95% CI, 0.59-0.96; P =.019) in the overall intention-to-treat population with a median follow-up of 35.2 months. In patients with centrally confirmed lymphoma subtypes (n = 773), the PFS HR was 0.68 (95% CI, 0.52-0.88), with a 24-month PFS rate of 72.7% vs 62.2% in favor of tafasitamab plus lenalidomide and R-CHOP (Tafa-Len-R-CHOP) vs R-CHOP alone.¹

“We believe that the combination of [Tafa-Len-R-CHOP] is a potential new standard for frontline therapy for patients with intermediate or high-risk [DLBCL] or [HGBL],” said lead investigator Georg Lenz, MD, of the University Hospital Münster in Germany, who presented the data during a premeeting press briefing.¹

The frontMIND Study Design

FrontMIND was a randomized, double-blind, placebo-controlled, global phase 3 trial enrolling 899 adults aged 18 to 80 years with previously untreated, high intermediate–risk or high-risk DLBCL or HGBL (International Prognostic Index [IPI] score 3-5; age-adjusted IPI 2-3 for patients aged ≤ 60 years) and an ECOG performance status of 0 to 2. Patients were required to have at least 1 measurable PET-positive lesion within 28 days of diagnostic biopsy.²

Patients were randomly assigned 1:1 to receive Tafa-Len-R-CHOP (n = 448) or R-CHOP with placebo (n = 451) for 6 cycles of 21 days each. Stratification factors included IPI/age-adjusted IPI score and geographic region. The primary end point was investigator-assessed PFS; key secondary end points included event-free survival (EFS), overall survival (OS), complete response (CR) rate, and overall response rate (ORR).²

Additional Efficacy Data

The 24-month PFS rate was 71.1% with Tafa-Len-R-CHOP vs 62.9% with R-CHOP alone, representing an absolute difference of 8.2 percentage points; at 36 months, rates were 67.3% vs 60.7%, respectively, with a δ of 6.6%. The median PFS had not been reached as of the data cutoff.¹

Among patients with centrally confirmed lymphoma subtypes, the 24-month PFS rate was 72.7% with Tafa-Len-R-CHOP vs 62.2% with R-CHOP—a difference of 10.5 percentage points—and the HR was 0.68 (95% CI, 0.52-0.88). According to the investigators, a PFS benefit with Tafa-Len-R-CHOP was observed across both activated B-cell–like and germinal center B-cell–like molecular cell-of-origin subtypes.¹

Tafa-Len-R-CHOP also significantly improved EFS compared with R-CHOP (HR, 0.79; 95% CI, 0.64-0.97; P =.026). The 24-month EFS rate was 65.0% vs 56.7%, and the 36-month EFS rate was 61.2% vs 54.8% in the Tafa-Len-R-CHOP and R-CHOP arms, respectively.¹

CR and ORR were similar between treatment arms. An interim OS analysis showed a numerical trend in favor of Tafa-Len-R-CHOP, with an HR of 0.85 (95% CI, 0.63-1.14; P =.270); the 24-month OS rates were 84.1% vs 80.5% and the 36-month rates were 81.1% vs 77.8% with Tafa-Len-R-CHOP vs R-CHOP, respectively. Overall, fewer deaths occurred in the Tafa-Len-R-CHOP arm (18.5%) than in the R-CHOP arm (21.7%); a final OS analysis is planned at 5 years.¹

Safety Findings

The addition of tafasitamab and lenalidomide to R-CHOP was associated with a manageable but increased toxicity burden compared with R-CHOP alone. Any-grade treatment-emergent adverse events (TEAEs) were similar across arms (98.6% vs 97.1%). Grade 3 or greater TEAEs occurred more frequently in the Tafa-Len-R-CHOP arm (86.7% vs 76.1% R-CHOP alone). The most common AEs were cytopenias and infectious events, consistent with the known safety profiles of the individual agents.¹

Discontinuations due to TEAEs occurred in 5.2% of patients in the Tafa-Len-R-CHOP arm vs 5.4% in the R-CHOP arm. Deaths due to TEAEs were reported in 5.9% vs 3.8% of patients, respectively. Importantly, the addition of tafasitamab and lenalidomide did not appear to compromise the delivery of the R-CHOP backbone; median relative dose intensities were high and equivalent between the 2 groups for all R-CHOP components across 6 cycles.¹

Implications and Future Directions

R-CHOP has been the cornerstone of first-line therapy for DLBCL for more than 2 decades; however, approximately 40% of patients with high-risk disease are not cured with this regimen, leaving a substantial unmet need for more effective frontline options.³

With the primary end point of PFS met, the data now position Tafa-Len-R-CHOP as a regimen capable of improving upon the decades-long standard of R-CHOP in patients with high-risk, newly diagnosed DLBCL or HGBL. Notably, the PFS benefit was observed regardless of molecular cell-of-origin subtype—a finding of particular clinical interest given that prior attempts to improve on R-CHOP have often shown differential efficacy by subtype.¹

When asked where the regimen fits into the broader treatment landscape alongside chimeric antigen receptor (CAR) T-cell therapy, Lenz noted that further data are needed to fully characterize the interaction between prior tafasitamab exposure and subsequent CAR T-cell efficacy but that preliminary observations from the frontMIND trial are reassuring.¹

“From what we know with tafasitamab, it does not impair subsequent CAR T-cell therapies. That’s also the preliminary data of the frontMIND study; when we looked at those patients relapsing and being treated with a CAR T-cell therapy, they still expressed CD19, and they still responded in the ballpark of what you would expect,” Lenz explained.¹ “So I would assume we're not impairing CAR T-cell efficacy, but obviously we need much more data to answer that in a solid manner.”

Regarding next steps, Incyte, the developer of tafasitamab, previously announced plans to file a supplemental biologics license application with the FDA for Tafa-Len-R-CHOP as a first-line treatment for adults with newly diagnosed DLBCL.³

DISCLOSURES: Lenz reported honoraria from AbbVie, ADC Therapeutics SA, AstraZeneca, BeiGene Ltd/BeOne Medicines, Bristol Myers Squibb, Exscientia, Genmab A/S, Gilead Sciences Inc, GlaxoSmithKline, Hexal AG, Immagene/Flindr Therapeutics BV, Incyte, Eli Lilly and Company, Miltenyi Biotec, MSD, Novartis, Pentixapharm Holding AG, Pierre Fabre, Roche Group/Genentech, and Sobi; a consulting or advisory role with AbbVie, ADC Therapeutics, AstraZeneca, BeiGene/BeOne, Bristol Myers Squibb, Exscientia, Genmab, Gilead Sciences, GlaxoSmithKline, Hexal, Immagene/Flindr, Incyte, Eli Lilly and Company, Miltenyi Biotec, MSD, Novartis, Pentixapharm, Pierre Fabre, Roche/Genentech, and Sobi; receipt of institutional research funding from AbbVie, AstraZeneca, Gilead Sciences, Novartis, Roche/Genentech, and Sobi; and expert testimony for Roche.

REFERENCES

1. Lenz G, Trněný M, Burke JM, et al. frontMIND: Phase 3 study of tafasitamab plus lenalidomide and R-Chop for patients with newly diagnosed diffuse large B-cell lymphoma. J Clin Oncol. 2026;44(suppl 17):LBA7000. 10.1200/JCO.2026.44.17_suppl.LBA7000

2. Tafasitamab + lenalidomide + R-CHOP versus R-CHOP in newly diagnosed high-intermediate and high risk DLBCL patients (frontMIND). ClinicalTrials.gov. Updated April 1, 2026. Accessed May 30, 2026. https://clinicaltrials.gov/study/NCT04824092

3. Incyte announces positive topline results from pivotal study of tafasitamab (Monjuvi/Minjuvi) as a first-line treatment for diffuse large B-cell lymphoma. News release. Incyte. January 5, 2026. Accessed May 30, 2026. https://tinyurl.com/3kcd54h2